Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 High Purity New England Appoints Chief Scientific Officer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

High Purity New England Appoints Chief Scientific Officer

Dr. Michael Quesenberry will serve as a subject-matter expert for bioprocess development.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

High Purity New England, a supplier of equipment, process systems, and custom solutions for the biopharma industry, has appointed a new chief scientific officer, Dr. Michael Quesenberry.
 
As a biopharma industry veteran, Quesenberry will bring his wealth of bioprocessing knowledge in both cGMP manufacturing and process development to the HPNE team, helping to advance the mission of the organization as it continues its high-growth trajectory.
 
With a Ph.D in Biochemistry and Molecular Biology from Columbia University, as well as a Bachelor of Science magna cum laude in Chemistry and Biophysics from Hampden-Sydney College, Quesenberry will serve as a subject-matter expert for bioprocess development. He will also spearhead a lot of new initiatives, including new product development, employee training, and the creation of a new laboratory and specialty materials and manufacturing workshop.
 
Prior to joining the HPNE team, Quesenberry began as an instrumentation scientist supporting dynamic light scattering and circular dichroism. He then transitioned into process development work at preclinical companies like Avaxia, Xencor, and Werewolf Therapeutics, and larger Phase I/II biotechs such as BMS, Pfizer, Lonza, and Pall Life Sciences. At Pall, Quesenberry started as subject matter expert across the portfolio and finished as certified trainer for all product lines. Among his other accomplishments, he has two patents to his name, and he has published more than 16 peer-reviewed Glycobiology-focused articles in the course of his research career.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters